Survivin as Predictive Biomarker for Development of Rheumatoid Arthritis
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 6,000
- 试验地点
- 1
- 主要终点
- Survivin positive
研究概览
简要总结
Purpose: to examine the possibility of using the onco-protein survivin as a predictive biomarker for identifying individuals at risk of developing rheumatoid arthritis within a cohort of patients seeking treatment for joint pain/stiffness. Secondly, to study survivin as a prognostic marker for joint destruction, refractory and highly active disease in patients with established RA.
详细描述
The study will analyse survivin levels in a non-selected material within a cohort of patients seeking help at their primary health care for joint pain, stiffness, swelling etc. Patients presenting with such symptoms (not explained by injury or other factors) are suspected to have an arthritic condition such as RA, and are routinely tested for presence of autoantibodies RF and ACPA. In this observational study we add measurement for survivin to the blood analyses of these patients. Information about patients expressing high levels of survivin will be reported to the referring doctor at the primary health care, and for patients not previously having been examined by a rheumatologist this will be offered.
The study will be performed at Sahlgrenska university hospital Gothenburg and Umeå university hospital.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients seeking treatment at the primary health care for problems with their joints (pain, stiffness).
排除标准
- •Patients diagnosed with RA
结局指标
主要结局
Survivin positive
时间窗: 1 year
Survivin positive: \> 0,45 ng/ml Survivin negative: \< 0,45 ng/ml
次要结局
未报告次要终点